Lovastatin Tablet
Product Images NDC 51407-253

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Lovastatin (NDC 51407-253). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Golden State Medical Supply, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

51407-251-60lb Lovastatin 10 mg Tabs.jpg (51407 251 60lb Lovastatin 10 mg Tabs)

Label for Lovastatin tablets, USP 10 mg, oral dosage form, containing 60 tablets. The label displays NDC 51407-251-60 and states that the product is manufactured by PLIVA HRVATSKA d.o.o. and packaged by GSMS Incorporated, Golden State Medical Supply, Inc. Storage instructions are included, as well as a barcode and a lot/expiration date area.*

FDA Label Image

51407-252-60lb Lovastatin 20 mg Tabs.jpg (51407 252 60lb Lovastatin 20 mg Tabs)

Label for Lovastatin Tablets, USP 20 mg by Golden State Medical Supply, Inc. The label displays the NDC 51407-252-60 and indicates a bottle containing 60 tablets. Storage instructions specify 20 to 25 degrees Celsius. The label includes dosing information reference and safety warnings, with a barcode and manufacturer details.*

FDA Label Image

51407-253-60lb Lovastatin 40 mg Tabs.jpg (51407 253 60lb Lovastatin 40 mg Tabs)

Lovastatin 40 mg tablets, USP, oral dosage form, in a 60-tablet package. The label includes the NDC number 51407-253-60 and states the product is Rx only. Manufactured by GSMS Incorporated and labeled by Golden State Medical Supply, Inc. The label also contains a barcode and storage instructions.*

FDA Label Image

Image 1

Chemical structure of lovastatin, depicting its molecular framework including multiple rings and functional groups representing the active ingredient lovastatin.*

FDA Label Image

Image 2

A line graph titled 'Acute Major Coronary Events (Primary Endpoint)' showing the proportion of participants without events over 6 years of follow-up. Two lines compare Lovastatin and placebo groups, with Lovastatin consistently showing higher event-free proportions. The graph notes a 37% risk reduction with Lovastatin (p < 0.001). The y-axis represents the proportion of participants without event, and the x-axis shows years of follow-up.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.